Cranberry and Recurrent Urinary Tract Infections: What Does the Updated Cochrane Review Show?

For years cranberry had a reputation as a home remedy for recurrent urinary tract infections, even though earlier large systematic reviews were skeptical about it. The latest, fifth update of the Cochrane review, from 2023 — now covering 50 studies and nearly 9,000 participants — changes that picture: in women with recurrent infections, cranberry products probably do meaningfully reduce the risk of another episode, though the effect is moderate and not visible in every patient group.

AKdr Anna KowalczykSeptember 2, 202612 min read

Table of contents

TL;DR — key takeaways

→A home remedy that divided scientists for years
→What the 2023 update of the Cochrane review showed
→Why the effect isn't the same across every group
→How cranberry is supposed to work — the mechanism
→The standardization problem — why not every cranberry product is the same
→Myth vs. fact
→What's worth knowing in practice
→Limitations of this evidence
→Our editorial recommendation

A home remedy that divided scientists for years

Cranberry (Vaccinium macrocarpon) is probably the best-known "natural" remedy for urinary tract infections — sold in pharmacies as juice, tablets, and capsules, recommended across generations as something "worth trying" for recurrent burning and frequent urination. For a long time, this popularity didn't quite match what large systematic reviews of clinical trials actually showed.

An earlier version of the Cochrane review, published in 2012, was skeptical of cranberry — pooling results from 24 trials involving 4,473 people, the authors found that cranberry products didn't significantly reduce the risk of symptomatic urinary tract infection compared with control groups, and they judged earlier, more optimistic conclusions to have been overstated, partly due to high dropout rates (poor tolerability of the juice's taste) and inconsistent active-ingredient content across commercial products.

That earlier, skeptical version of the review was cited for years as "proof" that cranberry doesn't work. Meanwhile, in November 2023 the fifth update of that same Cochrane review was published — with twice as many included studies and a more precise breakdown by patient subgroup. The conclusions are meaningfully different, and it's this newer version that represents the current state of knowledge and the main point of reference throughout this article.

What the 2023 update of the Cochrane review showed

Cranberries for preventing urinary tract infections

Moderate evidence

Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM · Cochrane Database of Systematic Reviews · 2023

The fifth update of the Cochrane review, covering 50 randomized trials and a total of 8,857 participants, comparing cranberry products (juice, tablets, capsules) against placebo, water, or no intervention. In the pooled analysis for symptomatic, culture-confirmed urinary tract infections, cranberry products reduced the risk of infection (6,211 participants: RR 0.70; 95% CI 0.58–0.84; I²=69%), with moderate-certainty evidence per GRADE. In the subgroup of women with recurrent urinary tract infections, the effect held: 8 studies, 1,555 participants, RR 0.74 (95% CI 0.55–0.99; I²=54%). Benefit was also observed in children (5 studies, 504 participants, RR 0.46; 95% CI 0.32–0.68) and in people susceptible to infection following urological interventions (6 studies, 1,434 participants, RR 0.47; 95% CI 0.37–0.61). No significant benefit was shown in elderly people in long-term care facilities, pregnant women, or people with bladder-emptying disorders.

View study

In other words: the new, substantially larger evidence base reverses the earlier, skeptical conclusion from 2012, at least for specific patient groups. Women with recurrent urinary tract infections — precisely the group most often targeted by cranberry product advertising — belong to the population in which the benefit is now confirmed with moderate certainty, not merely suggested by single, smaller trials.

Why the result changed between 2012 and 2023

It's not that cranberry "started working" — it's that the evidence base doubled (from 24 to 50 studies) and allowed for a more precise subgroup analysis. In 2012, all populations were pooled together, which diluted the effect visible specifically in women with recurrent infections. The newer, larger sample made it possible to separate these subgroups and show that the effect isn't uniform — it's clear in some populations and absent in others.

Why the effect isn't the same across every group

The benefit applies to specific populations, not everyone with a urinary tract infection

The Cochrane review clearly distinguishes groups in which cranberry products work from those in which no significant benefit is seen. The effect is documented in women with recurrent infections, in children, and in people following urological interventions that increase susceptibility to infection. There's no evidence of benefit, however, in elderly people in long-term care facilities, pregnant women, or patients with neurogenic bladder-emptying disorders (e.g., after spinal cord injury) — in these groups, trial results were inconsistent or pointed to no effect.

This distinction has practical significance: cranberry product advertising rarely specifies exactly who a given trial showed a benefit in. An elderly person in a care home reaching for cranberry for infection prevention is relying on evidence considerably weaker than that available to a younger woman with a history of recurrent urinary tract infections, even though both might buy exactly the same product off the same shelf.

How cranberry is supposed to work — the mechanism

The leading mechanistic hypothesis links cranberry's effect to type-A proanthocyanidins (PAC-A) — compounds that, in in-vitro studies, hinder the ability of Escherichia coli (responsible for the vast majority of urinary tract infections) to adhere to the epithelial cells lining the urinary tract. Unlike antibiotics, cranberry doesn't work by killing bacteria, but by making it harder for them to "latch onto" the bladder wall — which makes it potentially useful for prevention, not for treating an infection that has already developed.

Cranberry is prevention, not treatment for an active infection

None of the mechanisms or trial results discussed here suggest that cranberry is suitable for treating an already-established, symptomatic urinary tract infection. With typical symptoms (burning, frequent urination, lower abdominal pain), medical consultation is necessary and, if a bacterial infection is confirmed, appropriate antibiotic treatment — cranberry doesn't replace that treatment.

The standardization problem — why not every cranberry product is the same

One recurring methodological issue flagged in both the older and newer versions of the Cochrane review is the wide variability in active proanthocyanidin content across commercially available cranberry products. Juice, tablets, and capsules from different manufacturers can contain very different amounts of the active substance, and the label rarely provides this information in a way that allows a direct comparison with the doses used in clinical trials.

This is one explanation for the high heterogeneity (I²=69% for the overall result) observed in the meta-analysis — trials differed not only in population, but also in the actual dose of active substance participants received. In practice, this means that when choosing a specific product, it's hard to be sure it delivers a PAC-A dose comparable to the one that produced a benefit in clinical trials.

Myth vs. fact

Myth

Cranberry juice drunk every day "just in case" always helps prevent urinary tract infections, regardless of who's drinking it.

Fact

Current evidence points to a benefit primarily in women with a documented history of recurrent infections, in children, and in people following specific urological interventions — not in the general population drinking it "just in case." In elderly people in long-term care facilities or pregnant women, the Cochrane review found no significant benefit. On top of that, cranberry juice itself tends to be less well tolerated than tablets or capsules, which in some trials led to high dropout rates.

This distinction matters because the cost and effort of drinking cranberry juice regularly for years "just in case" may not pay off in populations where no benefit has been shown — whereas in the population where the benefit is documented (recurrent infections in women), the investment of time and money has a considerably stronger justification.

What's worth knowing in practice

Practical takeaways for anyone considering cranberry for prevention

The strongest evidence of benefit applies to women with a documented history of recurrent urinary tract infections — this is the main group for whom regular use is worth considering
Tablets and capsules tend to be better tolerated than juice, which reduces the risk of discontinuing use due to taste or stomach upset
It's worth looking for products with standardized proanthocyanidin (PAC) content, though in practice comparing brands is often hampered by inconsistent labeling
Cranberry is prevention, not treatment — with symptoms of an active infection (burning, frequent urination, pain), medical consultation is necessary
In elderly people, pregnant women, and patients with neurogenic bladder disorders, the evidence for benefit is much weaker — for these groups, the decision about prevention is worth discussing individually with a doctor
People taking anticoagulant medications (e.g., warfarin) should consult a doctor about regular, high cranberry intake given possible interactions described in the literature

Limitations of this evidence

Why we rate this evidence base as moderate, not strong

Moderate evidence

Although the Cochrane review covers as many as 50 studies and nearly 9,000 participants, the authors themselves rate the certainty of evidence for the main outcome as moderate (GRADE), mainly due to high heterogeneity between studies (I²=69%) and varying quality and standardization of the cranberry products used in individual trials. This isn't weak or preliminary evidence — it's a solid but heterogeneous base, in which the effect clearly depends on the population and the specific product.

Question	Short answer
Does cranberry prevent urinary tract infections?	Yes, in women with recurrent infections — the 2023 Cochrane review shows a 26% risk reduction (RR 0.74)
Does it work for everyone?	No — no significant benefit in elderly people in long-term care, pregnant women, or people with bladder disorders
Does it treat an already-established infection?	No — it's prevention, not a substitute for antibiotic treatment of an active infection
Juice or tablets?	Tablets/capsules tend to be better tolerated; active-ingredient dose is hard to compare across products
Is this a new discovery?	Partly — the previous 2012 review version was skeptical; the 2023 update (twice as many studies) changed the conclusions for specific groups

Cranberry and urinary tract infections at a glance

Our editorial recommendation

It's rare for the same series of systematic reviews to flip a conclusion within a decade from "probably doesn't work" to "probably works in specific people" — and that's exactly what makes this topic worth attention. This isn't a story about a miracle remedy, but about how a larger, better-designed evidence base allows a more precise answer to the question "for whom," instead of settling for a blanket "yes" or "no."

Cranberry isn't a universal remedy for urinary tract infections — it's a documented preventive option for a specific, well-defined group of women with recurrent infections. For that group, it's today one of the few "natural" interventions backed by a real, large meta-analysis rather than tradition alone.

Dr. Anna Kowalczyk, VitMode editorial team

Frequently asked questions

No. Cranberry acts preventively, making it harder for bacteria to adhere to the walls of the urinary tract, but it doesn't eliminate an infection that's already underway. With symptoms of an active infection (burning, frequent urination, pain), medical consultation is necessary and, if a bacterial infection is confirmed, appropriate antibiotic treatment.

The previous 2012 Cochrane review version covered 24 studies and 4,473 participants and found no significant benefit in the general population. The 2023 update doubled the number of included studies (to 50) and enabled a more precise subgroup analysis, which revealed a clear effect in specific populations, including women with recurrent infections — previously diluted by pooling all groups together.

The Cochrane review doesn't point to one best form — what matters is the content of active proanthocyanidins, not the product's form. In practice, tablets and capsules tend to be better tolerated than juice, which reduces the risk of discontinuing use, while standardizing the active-ingredient dose remains a problem regardless of form.

Generally yes, but people taking anticoagulant medications such as warfarin should consult a doctor about regular, high cranberry intake given possible interactions described in the literature. It's also worth remembering that cranberry juice contains sugars and calories, which matters for long-term, daily consumption.

The Cochrane review found no significant benefit in this specific population (elderly people in long-term care facilities), even though this group is frequently steered toward cranberry prevention. The decision about potential use is worth discussing individually with the treating doctor in this case, taking other risk factors into account.

The studies included in the Cochrane review typically assessed the preventive effect over periods of several months to a year of regular use, not after a one-time or short-term course. Cranberry is an intervention meant for systematic use over time, not an on-the-spot remedy for symptoms already being felt.

Yes — it's the fifth update of one of the most respected types of systematic review in medicine, covering 50 randomized trials and nearly 9,000 participants. The authors themselves rate the certainty of evidence as moderate (not the highest) due to heterogeneity between studies, which is worth treating as an honest caveat rather than a reason to dismiss the results entirely.

Sources

dr Anna Kowalczyk

PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging

Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.

Rzędy probówek z próbkami krwi w stojaku laboratoryjnym

5 Biomarkers Worth Knowing Before 40 — Signals Before Symptoms Appear

A standard "once-a-year blood count" often misses early signs of metabolic and hormonal issues. Here are five markers worth asking your doctor about, before anything starts to hurt.

7 min

August 1, 2026

Melatonin and Migraine in Children: Can a Supplement Replace Preventive Medication?

Migraine in children can seriously disrupt school, sleep, and daily life, and parents looking for a gentler alternative to prescription drugs increasingly come across melatonin as a preventive option. A carefully designed, randomized, placebo-controlled trial from the University of California, San Francisco, however, tells a much less clear-cut story than popular articles suggesting a ready-made solution.

11 min

September 2, 2026

Świeży korzeń imbiru na desce do krojenia

Ginger and Migraine: Does It Help During an Acute Attack, or Only for Prevention?

Ginger is sometimes recommended as a natural way to ease a migraine attack, often alongside classic triptans or as an add-on to standard treatment. A 2021 meta-analysis pooling three randomized trials shows a real effect on pain during an acute migraine attack — but that's a completely different question from preventing migraines in the first place, where the evidence is much weaker, and one trial found no advantage of ginger over placebo.

10 min

September 2, 2026

Lekarz notujący szczegóły podczas konsultacji pacjenta w gabinecie

TRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy

Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.

7 min

July 29, 2026

Related knowledge base entries

4.6

Lipid Panel

The lipid panel is one of the most important — and still one of the most frequently misread — preventive blood tests: 'total cholesterol' alone tells you less than the ratios between its fractions.

Badania krwiStrong evidence

4.5

How to Read a Basic Blood Test Panel

CBC, lipid panel, glucose, TSH — how to read the results of a basic blood panel so you catch early signals of a problem before it becomes a disease.